Anti-Human ITGB2 Therapeutic Antibody Fab Fragment (Hu23F2G (also known as LeukArrest and Rovelizumab))

This antibody immunologically reacts with the common β chain (CD18) of human leukocyte integrins and/or competes with mAb 60.3 for binding to human LFA-1, which is useful for the alleviation of symptoms associated with inflammatory disease states, and more particularly to the inhibition of inflammatory processes associated with the multiple sclerosis disease.
Supplier Creative Biolabs
Product # TAB-1582CL-F(E)
Pricing Inquiry
Type Humanized antibody
Host Human
Target CD18
Feedback